These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 8471415)

  • 1. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study.
    Skjelbo E; Gram LF; Brøsen K
    Br J Clin Pharmacol; 1993 Mar; 35(3):331-4. PubMed ID: 8471415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.
    Skjelbo E; Brøsen K; Hallas J; Gram LF
    Clin Pharmacol Ther; 1991 Jan; 49(1):18-23. PubMed ID: 1988236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.
    Brøsen K; Gram LF; Kragh-Sørensen P
    Ther Drug Monit; 1991 Mar; 13(2):177-82. PubMed ID: 2053127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
    Madsen H; Nielsen KK; Brøsen K
    Br J Clin Pharmacol; 1995 Apr; 39(4):433-9. PubMed ID: 7640151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs.
    Koyama E; Chiba K; Tani M; Ishizaki T
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1199-210. PubMed ID: 9190854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.
    Brøsen K; Otton SV; Gram LF
    Clin Pharmacol Ther; 1986 Nov; 40(5):543-9. PubMed ID: 3769385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.
    Brøsen K; Gram LF
    Clin Pharmacol Ther; 1988 Apr; 43(4):400-6. PubMed ID: 3356084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
    Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
    Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine.
    Brøsen K; Gram LF
    Eur J Clin Pharmacol; 1989; 37(2):155-60. PubMed ID: 2792169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.
    Koyama E; Tanaka T; Chiba K; Kawakatsu S; Morinobu S; Totsuka S; Ishizaki T
    J Clin Psychopharmacol; 1996 Aug; 16(4):286-93. PubMed ID: 8835703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation.
    Chiba K; Saitoh A; Koyama E; Tani M; Hayashi M; Ishizaki T
    Br J Clin Pharmacol; 1994 Mar; 37(3):237-42. PubMed ID: 8198931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
    Nielsen KK; Brøsen K; Hansen MG; Gram LF
    Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation.
    Knodell RG; Dubey RK; Wilkinson GR; Guengerich FP
    J Pharmacol Exp Ther; 1988 Jun; 245(3):845-9. PubMed ID: 3385644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.
    Sindrup SH; Brøsen K; Hansen MG; Aaes-Jørgensen T; Overø KF; Gram LF
    Ther Drug Monit; 1993 Feb; 15(1):11-7. PubMed ID: 8451774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4'-hydroxylation phenotypes.
    Koyama E; Sohn DR; Shin SG; Chiba K; Shin JG; Kim YH; Echizen H; Ishizaki T
    J Pharmacol Exp Ther; 1994 Nov; 271(2):860-7. PubMed ID: 7965806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study.
    Madsen H; Hansen TS; Brøsen K
    Pharmacogenetics; 1996 Dec; 6(6):513-9. PubMed ID: 9014200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
    Drøhse A; Bathum L; Brøsen K; Gram LF
    Br J Clin Pharmacol; 1989 May; 27(5):620-5. PubMed ID: 2757884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic metabolism of imipramine after prolonged administration of the drug to rats. An in vivo study.
    Melzacka M; Danek L; Adamus A
    Pol J Pharmacol Pharm; 1987; 39(4):379-86. PubMed ID: 3449809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Citalopram: interaction studies with levomepromazine, imipramine, and lithium.
    Gram LF; Hansen MG; Sindrup SH; Brøsen K; Poulsen JH; Aaes-Jørgensen T; Overø KF
    Ther Drug Monit; 1993 Feb; 15(1):18-24. PubMed ID: 8451775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The significance of cytochrome P450 gene superfamily for the clinical pharmacokinetics of drugs].
    Brøsen K
    Ugeskr Laeger; 1991 Feb; 153(6):417-22. PubMed ID: 2000644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.